Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

PURPOSE: Neoadjuvant CT-P6, a trastuzumab biosimilar, demonstrated equivalent efficacy to reference trastuzumab in a phase 3 trial of HER2-positive early-stage breast cancer (EBC) (NCT02162667). We report post hoc analyses evaluating pathological complete response (pCR) and breast pCR alongside addi...

Descripción completa

Detalles Bibliográficos
Autores principales: Esteva, F. J., Baranau, Y. V., Baryash, V., Manikhas, A., Moiseyenko, V., Dzagnidze, G., Zhavrid, E., Boliukh, D., Stroyakovskiy, D., Pikiel, J., Eniu, A. E., Li, R. K., Rusyn, A. V., Tiangco, B., Lee, S. J., Lee, S. Young, Yu, S. Y., Stebbing, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768896/
https://www.ncbi.nlm.nih.gov/pubmed/31428820
http://dx.doi.org/10.1007/s00280-019-03920-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768896/
https://www.ncbi.nlm.nih.gov/pubmed/31428820
http://dx.doi.org/10.1007/s00280-019-03920-4

Ejemplares similares